# HBV DNA is undetectable: why do I still need hepatitis B medicine?

URL: https://openhbv.bangbo.dev/articles/hbv-dna-undetectable-continue-treatment-en?locale=en
Canonical Markdown: https://openhbv.bangbo.dev/articles/hbv-dna-undetectable-continue-treatment-en.md?locale=en
Language: en
Translation key: hbv-dna-undetectable-continue-treatment
Topic: Treatment and Follow-up
Audience: People with chronic hepatitis B and their families
Region: Global
Published: 2026-10-14
Last reviewed: 2026-10-14
Review status: source_backed
Tags: Treatment, Monitoring, Serology

## Summary

Understand why undetectable HBV DNA does not automatically mean treatment can stop, and what to ask your doctor.

## Article

After taking antiviral medicine for a while, you may feel relieved to see “HBV DNA not detected” on your report. A natural question follows: if the virus cannot be detected, can I stop treatment?

**For someone receiving antiviral treatment for chronic hepatitis B, one undetectable HBV DNA result is not enough to decide that treatment can stop.** Other markers, liver health, and results over time also matter. [China chronic hepatitis B guideline, 2022](https://pmc.ncbi.nlm.nih.gov/articles/PMC12677433/)

## What does “not detected” mean?

No viral DNA was detected in that blood sample; this does not prove that HBV has been completely eliminated. “Below the quantification limit” is different: a report saying “<15 IU/mL, detected” means viral DNA was found, but could not be measured accurately. Read the full report. [CDC laboratory guidance](https://www.cdc.gov/hepatitis/php/surveillance-guidance/hepatitis-b.html)

## Is undetectable DNA the same as losing surface antigen?

HBV DNA measures circulating viral replication. Hepatitis B surface antigen, or HBsAg, is a separate marker: undetectable DNA does not automatically mean HBsAg has disappeared.

Functional cure generally includes sustained HBsAg loss and undetectable HBV DNA after treatment ends. Viral genetic material may still remain in liver cells. Viral suppression, surface antigen loss, and complete viral elimination are different outcomes. [China guideline: definitions](https://pmc.ncbi.nlm.nih.gov/articles/PMC12677433/)

## Why continue taking medicine?

Medicines such as entecavir and tenofovir suppress viral replication, slow cirrhosis progression, reduce liver cancer risk, and improve long-term survival. Better results can mean treatment is working. WHO notes that most people who start chronic hepatitis B treatment need to continue it for life. [WHO hepatitis B fact sheet](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b)

## Can anyone stop treatment?

Some carefully selected patients can. Guidelines differ; clinicians assess cirrhosis, HBeAg and HBsAg status, duration of viral suppression, and reliable follow-up. People with cirrhosis should be particularly cautious. Stopping can cause viral rebound, hepatitis flares, and sometimes liver decompensation. Any stopping plan must include monitoring and criteria for restarting treatment. [EASL 2025 hepatitis B guideline](https://www.hepb.org/assets/Uploads/EASL-guidelines-May-2025.pdf)

## Action checklist: what to ask at your next visit

Continue your current prescription and bring previous reports. Ask your doctor:

- Was HBV DNA not detected, or detected below the quantification limit?
- What do my surface antigen, liver tests, and fibrosis assessment show?
- Do I meet the criteria to discuss stopping treatment?
- If I eventually stop, when will I have tests, and what would require restarting?

An undetectable result is encouraging. Work with your doctor to maintain the benefit you have achieved.

*This article provides education about oral antiviral treatment for chronic hepatitis B, not an individual instruction to stop medicine. Preventive treatment during pregnancy or immunosuppression requires a separate assessment.*


## References

1. WHO Hepatitis B Fact Sheet
   Organization: World Health Organization
   Source page: https://openhbv.bangbo.dev/sources/who-hepatitis-b-fact-sheet?locale=en
   Source Markdown: https://openhbv.bangbo.dev/sources/who-hepatitis-b-fact-sheet.md?locale=en
   Original URL: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
   Source type: fact_sheet
   Published: not listed
   Source updated: not listed
   Last checked: 2026-06-26
   Accessed: 2026-10-14
   Credibility note: 权威公共卫生来源
   Summary: WHO 关于乙肝传播、预防、疫苗、检测、治疗和全球公共卫生影响的概览。
   Supports: Treatment
   Editor note: Supports the benefits of entecavir and tenofovir and the need for long-term treatment for most patients.
2. CDC Hepatitis B Surveillance Guidance
   Organization: Centers for Disease Control and Prevention
   Source page: https://openhbv.bangbo.dev/sources/cdc-hepatitis-b-surveillance-guidance?locale=en
   Source Markdown: https://openhbv.bangbo.dev/sources/cdc-hepatitis-b-surveillance-guidance.md?locale=en
   Original URL: https://www.cdc.gov/hepatitis/php/surveillance-guidance/hepatitis-b.html
   Source type: guideline
   Published: not listed
   Source updated: not listed
   Last checked: 2026-10-14
   Accessed: 2026-10-14
   Credibility note: US national public-health agency; laboratory interpretation guidance
   Summary: Explains HBV laboratory markers, including detectable DNA below the lower limit of quantification.
   Supports: Interpreting Hepatitis B Laboratory Results
   Editor note: Supports the distinction between undetectable HBV DNA and detectable DNA below the quantification limit; this surveillance source is not used to set treatment stopping criteria.
3. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022)
   Organization: Journal of Clinical and Translational Hepatology
   Source page: https://openhbv.bangbo.dev/sources/guidelines-for-the-prevention-and-treatment-of-chronic-hepatitis-b-version-2022?locale=en
   Source Markdown: https://openhbv.bangbo.dev/sources/guidelines-for-the-prevention-and-treatment-of-chronic-hepatitis-b-version-2022.md?locale=en
   Original URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC12677433/
   Source type: guideline
   Published: 2023-11-28
   Source updated: 2022-12-31
   Last checked: 2026-06-26
   Accessed: 2026-10-14
   Credibility note: 中国专业学会指南英文发表版本
   Summary: 中国《慢性乙型肝炎防治指南（2022年版）》的英文发表版本，便于非中文读者检索中国慢乙肝筛查、诊断、预防和治疗建议。
   Supports: Definitions and nucleos(t)ide analogue treatment duration
   Editor note: Supports functional cure terminology and the need to consider more than a single HBV DNA result before stopping treatment.
4. EASL 2025 Clinical Practice Guidelines on Hepatitis B
   Organization: European Association for the Study of the Liver
   Source page: https://openhbv.bangbo.dev/sources/easl-2025-clinical-practice-guidelines-on-hepatitis-b?locale=en
   Source Markdown: https://openhbv.bangbo.dev/sources/easl-2025-clinical-practice-guidelines-on-hepatitis-b.md?locale=en
   Original URL: https://www.hepb.org/assets/Uploads/EASL-guidelines-May-2025.pdf
   Source type: guideline
   Published: 2025-05-15
   Source updated: 2025-05-15
   Last checked: 2026-06-26
   Accessed: 2026-10-14
   Credibility note: 欧洲专业肝病学会临床指南
   Summary: EASL 2025 年乙肝临床实践指南，覆盖诊断、治疗目标、治疗适应证、治疗选择、肝癌监测、特殊人群、HBV 再激活预防、移植后照护、预防策略和未来研究问题。
   Supports: Stopping nucleos(t)ide analogue therapy
   Editor note: Supports clinician selection, close follow-up, retreatment planning, and the risks of relapse and decompensation after discontinuation.

## Use And Safety Notes

This Markdown version is provided for search, retrieval, and LLM citation workflows. OpenHBV is a health education site, not a personal diagnosis or treatment service. Use the references above to verify medical claims, and consult qualified clinicians for individual decisions.